What you carry at this position in your DNA and what research says about it.
Blood Clotting and Heart Health: 10/10 evidence, 23 publications.
You're viewing every possible genotype for this variant.
None of these is your result. Use the genotype toggle to compare them, then sign up and upload your DNA to see which one is yours.
Sample genotype (not yours): G/G
Typical Clotting Speed and Cardiovascular Risk
Standard levels of clotting factor VII maintain typical blood clotting speed and baseline cardiovascular risks. No elevated health risks are associated with this common genetic profile.
What this genotype means: Typical blood clotting speed; Standard baseline stroke and heart risk.
Sample genotype (not yours): A/A
Slowest Clotting and Lowest Stroke Risk
Significantly lower factor VII levels provide strong protection against cardiovascular events like stroke and heart attacks. Sensitivity to the blood-thinner warfarin is increased, requiring careful monitoring if prescribed.
What this genotype means: Significantly slower blood clotting; Lower risk of heart attack and stroke; Increased sensitivity to warfarin.
Sample genotype (not yours): G/A
Slower Clotting and Lower Stroke Risk
Reduced circulating factor VII levels lead to slightly slower blood clotting and a lower risk of ischemic stroke. This provides a natural protective effect for cardiovascular health.
What this genotype means: Slightly slower blood clotting; Reduced risk of ischemic stroke.
Gene function and biological role
Gene Function: Coagulation factor VII is a key protein in the coagulation cascade, initiating blood clotting when blood vessels are damaged [1]. It works alongside tissue factor to activate downstream proteins, ultimately forming a stable fibrin clot [1]. Variations in this gene can significantly alter the amount or activity of circulating factor VII in the bloodstream [2]. This directly impacts how quickly or slowly blood clots, influencing baseline cardiovascular risk [2].
Variant Impact: Replacing the amino acid arginine with glutamine at position 413 alters the secretion and processing of factor VII [3]. This structural change reduces circulating levels and activity of the protein [3]. Slower clot formation occurs as a direct result of this reduced activity [4]. Consequently, the change is widely studied for its protective effects against cardiovascular events and its influence on blood-thinning medications [5].
Key Insight: The minor A allele of this variant acts as a natural, mild blood thinner, reducing clotting factor VII levels by up to 43% and lowering stroke risk.
Location: F7. Chromosome 13 · 13q34 · 113.1 Mb
Estimated prevalence by population
Global 78.2%; European 79.4%; African 77.3%; East Asian 90.7%; South Asian 52.7%; Americas 78.2%; Ashkenazi 63.1%; Finnish 86.5%; Middle Eastern 67.2%; Amish 68.5%.
Estimated GG genotype frequency.
Global 20.3%; European 19.4%; African 21.3%; East Asian 9.1%; South Asian 39.8%; Americas 20.5%; Ashkenazi 32.7%; Finnish 13.0%; Middle Eastern 29.6%; Amish 28.5%.
Estimated GA genotype frequency.
Global 1.5%; European 1.2%; African 1.5%; East Asian 0.2%; South Asian 7.5%; Americas 1.3%; Ashkenazi 4.2%; Finnish 0.5%; Middle Eastern 3.3%; Amish 3.0%.
Estimated AA genotype frequency.
Showing effects for G/G genotype
Cardiovascular & Metabolic
Coagulation & Clotting
Blood Clotting Speed. Evidence: 10/10. Source: PMID 35552711. Typical Speed.
Stroke
Stroke. Evidence: 4/10. Source: PMID 21114618. Typical Risk.
Hypertension
Blood Pressure. Evidence: 4/10. Source: PMID 22815813. Typical.
Pharmacogenomics
Anticoagulant & Blood Thinner Response
Warfarin Sensitivity. Evidence: 5/10. Source: PMID 22071881. Typical Response.
Showing effects for A/A genotype
Blood Clotting Speed. Evidence: 10/10. Source: PMID 35552711. Slowest Clotting.
Stroke. Evidence: 4/10. Source: PMID 21114618. Lower Risk.
Blood Pressure. Evidence: 4/10. Source: PMID 22815813. Lower.
Warfarin Sensitivity. Evidence: 5/10. Source: PMID 22071881. Increased Sensitivity.
Showing effects for G/A genotype
Blood Clotting Speed. Evidence: 10/10. Source: PMID 35552711. Slower Clotting.
Blood Pressure. Evidence: 4/10. Source: PMID 22815813. Slightly Lower.
What this genotype means for the people who carry it
Sample genotype: GG (Homozygous)
Production of coagulation factor VII remains at standard baseline levels with this common genotype [1]. Normal clotting activity supports wound healing but maintains typical risks for cardiovascular events like stroke [2]. Standard prothrombin times are expected, reflecting a typical rate of clot formation [3]. Lacking the protective A allele means there is no genetically lowered risk for heart disease, but there is also no elevated risk [2]. Response to blood-thinning medications like warfarin is typical [4].
Typical blood clotting speed; Standard baseline stroke and heart risk.
Sample genotype: AA (Homozygous)
Two copies of the A allele reduce circulating factor VII levels and activity by up to 43% [1]. Slower blood clotting is reflected in a longer prothrombin time [2]. Strong protection against cardiovascular issues, including a lower risk of heart attacks and ischemic strokes, is a major benefit of this genotype [3]. Better blood pressure regulation is also commonly observed [4]. However, treatment with the blood-thinner warfarin carries a higher risk of over-anticoagulation and bleeding, requiring careful dose monitoring [5].
Significantly slower blood clotting; Lower risk of heart attack and stroke; Increased sensitivity to warfarin.
Sample genotype: GA (Heterozygous)
A single copy of the A allele reduces the activity and concentration of clotting factor VII by approximately 20% to 30% [1]. This reduction in clotting activity provides a natural, mild protective effect against unwanted blood clots in the blood vessels [2]. Lower risk of experiencing an ischemic stroke is a key benefit of this slower clot formation [2]. Research also suggests a potential benefit for blood pressure regulation, contributing to overall cardiovascular health [3]. Abnormal bleeding is not typically a concern under normal circumstances [4].
Slightly slower blood clotting; Reduced risk of ischemic stroke.
Variants with shared genetic architecture
rs1354034 · ARHGEF3 Gene · Chr 3 · Platelet Count and Size
rs1613662 · GP6 Gene · Chr 19 · Venous Thrombosis Risk
rs1671152 · GP6 Gene · Chr 19 · Platelet Aggregation
Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
Content updated August 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com